Cardiovascular and Renal Benefit of Sodium-Glucose Cotransporter Type 2 Inhibitors in Patients With Type 2 Diabetes

Steven Ho Man Lam; Uazman Alam; Professor Gregory Lip

doi:10.1016/j.amjcard.2024.05.001

Back

Cardiovascular and Renal Benefit of Sodium-Glucose Cotransporter Type 2 Inhibitors in Patients With Type 2 Diabetes

Letter 2024 en

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Article2025

Sodium-Glucose Cotransporter-2 Inhibitors and Arrhythmias

Vikash Jaiswal, Song Peng Ang, Danisha Kumar, Novonil Deb, Akash Jaiswal, Amey Joshi, Yusra Nasir, Dhrubajyoti Bandyopadhyay, Erin D. Michos, Emelia Benjamin, Gregg C. Fonarow

Article2025

Sodium Glucose Cotransporter 2 Inhibitors Across the Spectrum of Cardiovascular Kidney Metabolic Syndrome

Kevin Bryan Lo, Karim Iskarous, Rajiv Sankaranarayanan

Article2022

Sodium‐glucose cotransporter 2 inhibitors: An additional management option for patients with atrial fibrillation?

Riccardo Proietti, Professor Gregory Lip

Article2021

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis

Hang‐Long Li, Professor Gregory Lip, Qi Feng, Yue Fei, Yi-Kei Tse, Mei-zhen Wu, Qing-Wen Ren, Hung‐Fat Tse, Bernard-M. Y. Cheung, Kai‐Hang Yiu

Preprint2023

New-onset syncope in diabetic patients treated with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors: A Chinese population-based cohort study

Xinyi Gao, Nan Zhang, Lei Lü, Tianyu Gao, Oscar Hou In Chou, Wing Tak Wong, Carlin Chang, Abraham Ka Chung Wai, Professor Gregory Lip, Qingpeng Zhang, Gary Tse, Tong Liu, Jiandong Zhou